Liver transplantation for primary sclerosing cholangitis

Area of Science:

• Hepatology
• Transplantation Surgery
• Gastroenterology

Background:

• Primary sclerosing cholangitis (PSC) is a chronic liver disease often leading to cirrhosis.
• While interventional radiology and surgery improve survival, liver transplantation is the definitive treatment for advanced PSC.
• Established prognostic models guide treatment, but real-world transplantation outcomes require continuous evaluation.

Purpose of the Study:

• To evaluate the efficacy and long-term outcomes of liver transplantation in patients with primary sclerosing cholangitis.
• To identify factors influencing patient survival post-liver transplantation for PSC.
• To assess the incidence and implications of recurrent PSC after liver transplantation.

Main Methods:

• Analysis of actuarial patient survival rates at one and five years post-liver transplantation.
• Comparison of survival data with established prognostic models for PSC.
• Identification of risk factors, including cholangiocarcinoma and inflammatory bowel disease, affecting post-transplant outcomes.

Main Results:

• One- and five-year actuarial survival rates after liver transplantation for PSC exceed 90%.
• Cholangiocarcinoma is a significant adverse prognostic factor, whereas inflammatory bowel disease and prior biliary surgery do not negatively impact survival.
• Recurrent PSC occurs in 10%-20% of post-transplant patients.

Conclusions:

• Liver transplantation provides a high survival rate for PSC patients with cirrhosis.
• Close monitoring for recurrent PSC is crucial due to its 10%-20% incidence and potential long-term complications.
• Longer follow-up periods are recommended for PSC patients post-liver transplantation to manage potential recurrence and other complications.